[{"id":"4686c90a-b844-4de3-97d1-0c8afa66960c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05081492","created_at":"2021-10-18T12:53:08.385Z","updated_at":"2024-07-02T16:35:24.629Z","phase":"Phase 1","brief_title":"CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT05081492","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CHECKvacc (CF33-hNIS-antiPDL1) • VAXinia (CF33-hNIS)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 09/22/2024","primary_completion_date":" 09/22/2024","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-01-04"}]